Climb Bio hosts virtual investor event announcing positive topline Phase 1 data for subcutaneous budoprutug showing robust B-cell depletion comparable to IV, with initial trial readouts anticipated in June and Q4 2026.
Key takeaways
Robust B-cell depletion observed with budoprutug SC formulation in healthy volunteers, similar to IV at matched doses, supporting advancement to autoimmune patients.
Budoprutug SC generally safe and well-tolerated in Phase 1 trial.
ITP Phase 1b/2a initial data from low dose cohort expected June 2026.
pMN Phase 2 and SLE Phase 1b initial data expected Q4 2026.
Fast Track Designation received for budoprutug in pMN.
Investor event webcast available at climbbio.com with replay.